52505-46-1

Basic information

• Product Name: ETHYL 3-AMINOTHIENO[2,3-B]PYRIDINE-2-CARBOXYLATE
• Synonyms: AKOS 94297;ETHYL 3-AMINOTHIENO[2,3-B]PYRIDINE-2-CARBOXYLATE;3-aminothieno[2,3-b]pyridine-2-carboxylic acid ethyl ester
• CAS NO: 52505-46-1
• Molecular Formula: C₁₀H₁₀N₂O₂S
• Molecular Weight: 222.26
• Product Categories: Heterocycles series;Esters;Fused Ring Systems;Building Blocks;Thieno[x,x-y]pyridine
• Mol File: 52505-46-1.mol

Chemical Properties

• Melting Point: 183 °C
• Boiling Point: 386.034 °C at 760 mmHg
• Flash Point: 187.267 °C
• Appearance: /
• Density: 1.364 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.675
• PKA: 4.96±0.40(Predicted)
• CAS DataBase Reference: ETHYL 3-AMINOTHIENO[2,3-B]PYRIDINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-AMINOTHIENO[2,3-B]PYRIDINE-2-CARBOXYLATE(52505-46-1)
• EPA Substance Registry System: ETHYL 3-AMINOTHIENO[2,3-B]PYRIDINE-2-CARBOXYLATE(52505-46-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 52505-46-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3-AMINOTHIENO[2,3-B]PYRIDINE-2-CARBOXYLATE is used as a chemical intermediate for the synthesis of pharmaceutical drugs, leveraging its unique structural features to contribute to the development of new medicinal compounds.
Used as a Reference Standard in Chemical Analysis:
In the field of chemical analysis, ETHYL 3-AMINOTHIENO[2,3-B]PYRIDINE-2-CARBOXYLATE serves as a reference standard, ensuring the accuracy and reliability of analytical methods by providing a known quantity and quality for comparison and calibration purposes.

InChI:InChI=1/C10H10N2O2S/c1-2-14-10(13)8-7(11)6-4-3-5-12-9(6)15-8/h3-5H,2,11H2,1H3

Upstream product

• 52505-45-0 2-mercaptopyridine-3-carbonitrile 
• 105-39-5 chloroacetic acid ethyl ester 
• 20577-26-8 2-bromonicotinonitrile 
• 623-51-8 ethyl 2-sulfanylacetate 
• 6602-54-6 2-chloro-3-pyridinecarbonitrile 

Downstream Products

• 55115-79-2 Pyrido<3',2':4,5>thieno<3,2-d>pyrimidin-4(1H)-one 
• 371943-54-3 C₁₇H₁₄N₂O₃S 
• 72832-23-6 ethyl 3-bromothieno(2,3-b)pyridine-2-carboxylate 
• 58327-75-6 3-aminothieno[2,3-b]pyridine-2-carboxylic acid 
• 59944-78-4 ethyl thieno[2,3-b]pyridine-2-carboxylate 
• 371944-56-8 2-phenylpyrido[3',2':4,5]thieno[3,2-d]pyrimidin-4(3H)-one 
• 816424-66-5 lithium 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxylate 
• 816464-46-7 tert-butyl 4-[({3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl}carbonyl)amino]piperidine-1-carboxylate 
• 816464-41-2 tert-butyl (3R)-3-[({3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridin-2-yl}carbonyl)amino]pyrrolidine-1-carboxylate 
• 816464-54-7 3-[(2,4-difluorophenyl)amino]-N-[(1S,2S)-2-hydroxycyclopentyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 
• 816464-55-8 3-[(2,4-difluorophenyl)amino]-N-[(1R,2R)-2-hydroxycyclopentyl]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 
• 816464-56-9 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-N-[(3R)-pyrrolidinyl-3-yl]-6,7-dihydrothieno[2,3-b]-2-carboxamide 
• 816464-63-8 3-[(2,4-difluorophenyl)amino]-6-oxo-7-phenyl-N-(piperidin-4-yl)-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 
• 816464-59-2 N-(azetidin-3-yl)-3-[(4-fluoro-3-methylphenyl)amino]-6-oxo-7-phenyl-6,7-dihydrothieno[2,3-b]pyridine-2-carboxamide 

Relevant articles and documents

GLUCOSE UPTAKE INHIBITORS AND USES THEREOF

The present invention relates to novel compounds that modulate cellular glucose uptake by affecting various targets, including, but not limited to those related to glycolysis and known transporters/co-transporters of the GLUT family. The compounds according to the invention are useful for treating cancer such as: neuroendrocrine neoplasms, gastrointestinal stromal tumors (GIST), renal cell carcinoma, paraganglioma, pheochromocytoma, pituitary adenoma, colorectal cancer, lung cancer, gastric cancer, pancreatic cancer sarcoma, head and neck cancer, melanoma, ovarian cancer and other cancers that rely on high levels of glycolysis for survival and proliferation; as well as in treating of autoimmune diseases, inflammation, infectious diseases, and metabolic diseases.

cGAS ANTAGONIST COMPOUNDS

Disclosed are novel compounds of Formula (I) that are cGAS antagonists, methods of preparation of the compounds, pharmaceutical compositions comprising the compounds, and their use in medical therapy.

New annelated thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidines, with potent anticancer activity, designed through VLAK protocol

Drug design was performed through the Virtual Lock-and-Key (VLAK) protocol. This in silico approach allowed to select new annelated thienotriazolopyrimidine derivatives, potentially antitumor drugs. Starting from benzothieno[2,3-e][1,2,3]triazolo[1,5-a]py

Synthesis and biological evaluation of 2-(alkoxycarbonyl)-3-anilinobenzo[b] thiophenes and thieno[2,3-b]pyridines as new potent anticancer agents

Two new series of inhibitors of tubulin polymerization based on the 2-(alkoxycarbonyl)-3-(3′,4′,5′-trimethoxyanilino)benzo[b] thiophene and thieno[2,3-b]pyridine molecular skeletons were synthesized and evaluated for antiproliferative activity on a panel

Design, synthesis, and structure-activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the

TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS

Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein: W is O, N-H, N-(C1-C10 alkyl) or S; each X is independently CH or N; R1 is a 5 to 7-membered saturated or unsaturated, optionally substituted heterocycle containing at least 1 heteroatom selected from N or O; R2 is (LQ)mY; and each R3 is independently H, C1-C10 alkyl, aryl or heteroaryl, are surprisingly found to be inhibitors of PI3K-p110δ, and therefore have utility in therapy.

SPIRO-RING COMPOUND

The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.

HETEROCYCLIC COMPOUND

The present invention provides a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein each symbol is as in the specification, or a salt thereof.

THIENO-PYRIDINONE DERIVATIVES AS KINASE INHIBITORS

A series of thieno[2,3-b]pyridin-6(7H)-one derivatives, substituted in the 3-position by an arylcarbonyl or heteroarylcarbonyl moiety, being inhibitors of p38 MAP kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders.

BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS

A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 6-oxo-6,7-dihydrothieno[2,3-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or preventi